Targeting ATP2B1 impairs PI3K/Akt/FOXO signaling and reduces SARS-COV-2 infection and replication
Pasqualino De Antonellis, Veronica Ferrucci, Marco Miceli, Francesca Bibbò, Fatemeh Asadzadeh, Francesca Gorini, Alessia Mattivi, Angelo Boccia, Roberta Russo, Immacolata Andolfo, Vito Alessandro Lasorsa, Sueva Cantalupo, Giovanna Fusco, Maurizio Viscardi, Sergio Brandi, Pellegrino Cerino, Vittoria Monaco, Dong-Rac Choi, Jae‐Ho Cheong, Achille Iolascon, Stefano Amente, Maria Monti, Luca L. Fava, Mario Capasso, Hong-Yeoul Kim, Massimo Zollo
Abstract
Abstract ATP2B1 is a known regulator of calcium (Ca 2+ ) cellular export and homeostasis. Diminished levels of intracellular Ca 2+ content have been suggested to impair SARS-CoV-2 replication. Here, we demonstrate that a nontoxic caloxin-derivative compound (PI-7) reduces intracellular Ca 2+ levels and impairs SARS-CoV-2 infection. Furthermore, a rare homozygous intronic variant of ATP2B1 is shown to be associated with the severity of COVID-19. The mechanism of action during SARS-CoV-2 infection involves the PI3K/Akt signaling pathway activation, inactivation of FOXO3 transcription factor function, and subsequent transcriptional inhibition of the membrane and reticulum Ca 2+ pumps ATP2B1 and ATP2A1, respectively. The pharmacological action of compound PI-7 on sustaining both ATP2B1 and ATP2A1 expression reduces the intracellular cytoplasmic Ca 2+ pool and thus negatively influences SARS-CoV-2 replication and propagation. As compound PI-7 lacks toxicity in vitro, its prophylactic use as a therapeutic agent against COVID-19 is envisioned here.